journal
MENU ▼
Read by QxMD icon Read
search

Future Oncology

journal
https://www.readbyqxmd.com/read/30019968/optimal-prophylaxis-of-chemotherapy-induced-nausea-and-vomiting-for-moderately-emetogenic-chemotherapy-a-meta-analysis
#1
Yaxiong Zhang, Xue Hou, Rong Zhang, Gang Chen, Yan Huang, Yunpeng Yang, Yuanyuan Zhao, Wenfeng Fang, Shaodong Hong, Shiyang Kang, Ting Zhou, Zhonghan Zhang, Xi Chen, Li Zhang
AIM: We compare neurokinin-1 receptor antagonist (NK-1RA)-based triple regimen and conventional duplex regimen for antiemetic efficacy for patients with moderately emetogenic chemotherapy (MEC). Patients & methods: Pooled risk ratios (RRs) were used to evaluate the complete response and no significant nausea. The results were separately analyzed for pure MEC regimens, carboplatin-based regimens and oxaliplatin-based regimens. RESULTS: Ten trials focused on MEC involving 2928 cancer patients using NK-1RA triple regimens or conventional duplex regimen were included...
July 18, 2018: Future Oncology
https://www.readbyqxmd.com/read/30019964/algorithm-for-comorbidities-associations-length-of-stay-and-mortality-acalm
#2
Rahul Potluri
No abstract text is available yet for this article.
July 18, 2018: Future Oncology
https://www.readbyqxmd.com/read/30019947/the-next-generation-of-therapy-for-multiple-myeloma-a-review-of-ongoing-clinical-trials-utilizing-clinicaltrials-gov
#3
Peter Barth, Colin Vale, Alison B Chambers, John L Reagan
The therapeutic armamentarium for multiple myeloma has grown significantly over the past decade. We characterized ongoing multiple myeloma clinical trials utilizing ClinicalTrials.gov . A search of ClinicalTrials.gov on 21 April 2017 returned 239 therapeutic interventional trials in multiple myeloma. A majority (84.1%) of trials are early-phase (I/II). Immunotherapies are significantly more likely to be studied in Phase I trials than Phase II trials (p = 0.0049). Primary sponsor (academic, cooperative group, industry) is significantly associated with phase of trial (p = 0...
July 18, 2018: Future Oncology
https://www.readbyqxmd.com/read/30019940/tailoring-breast-cancer-therapies-to-reduce-mortality-and-improve-quality-of-life-san-antonio-breast-cancer-symposium-2017-part-2
#4
John R Benson, Ismail Jatoi
The 40th annual San Antonio Breast Cancer Symposium was convened in San Antonio, TX, USA on 5-9 December 2017. More than 7500 clinicians and scientists from around the world participated in the symposium which featured a range of presentations and keynote talks pertaining to breast cancer screening, prevention, loco-regional and systemic therapies. This two-part report highlights a selection of important studies presented at this premier breast cancer event with part 1 focusing on dose-intense radiotherapy, perioperative endocrine therapy, duration of bisphosphonates, immunotherapy, ovarian function suppression and acupuncture...
July 18, 2018: Future Oncology
https://www.readbyqxmd.com/read/30019936/analysis-of-risk-factors-of-lymph-node-metastasis-in-rectal-neuroendocrine-neoplasms-using-multicenter-data
#5
Gengzhou Wei, Xingyu Feng, Wei Wang, Yu Zhang, Yujie Zeng, Minhu Chen, Ye Chen, Jie Chen, Zhiwei Zhou, Yong Li
AIM: This study was conducted to analyze the risk factors associated with lymph node metastasis in rectal neuroendocrine neoplasms (NENs). MATERIALS & METHODS: A total of 419 patients with rectal NENs were enrolled. A univariate analysis of risk factors of lymph node metastasis was conducted using a χ2 test, and a multivariate analysis was conducted using a logistic regression analysis. RESULTS: Univariate and multivariate regression analysis revealed that tumor size, G grade and the depth of tumor invasion were independent risk factors for lymph node metastasis (p < 0...
July 18, 2018: Future Oncology
https://www.readbyqxmd.com/read/30019928/mirna-in-a-multiomic-context-for-diagnosis-treatment-monitoring-and-personalized-management-of-metastatic-breast-cancer
#6
Pavol Zubor, Peter Kubatka, Zuzana Dankova, Alexandra Gondova, Karol Kajo, Jozef Hatok, Marek Samec, Marianna Jagelkova, Stefan Krivus, Veronika Holubekova, Jan Bujnak, Zuzana Laucekova, Katarina Zelinova, Igor Stastny, Marcela Nachajova, Jan Danko, Olga Golubnitschaja
Metastatic breast cancer is characterized by aggressive spreading to distant organs. Despite huge multilevel research, there are still several important challenges that have to be clarified in the management of this disease. Therefore, recent investigations have implemented a modern, multiomic approach with the aim of identifying specific biomarkers for not only early detection but also to predict treatment responses and metastatic spread. Specific attention is paid to short miRNAs, which regulate gene expression at the post-transcriptional level...
July 18, 2018: Future Oncology
https://www.readbyqxmd.com/read/30019918/tailoring-breast-cancer-therapies-to-reduce-mortality-and-improve-quality-of-life-san-antonio-breast-cancer-symposium-2017-part-1
#7
John R Benson, Ismail Jatoi
The 40th annual San Antonio Breast Cancer Symposium was convened in San Antonio, Texas on 5-9 December 2017. More than 7500 clinicians and scientists from around the world participated in the symposium which featured a range of presentations and keynote talks pertaining to breast cancer screening, prevention, loco-regional and systemic therapies. This two-part report highlights a selection of important studies presented at this premier breast cancer event with part 1 focusing on dose-intense radiotherapy, perioperative endocrine therapy, duration of bisphosphonates, immunotherapy, ovarian function suppression and acupuncture...
July 18, 2018: Future Oncology
https://www.readbyqxmd.com/read/30019915/effects-of-sox15-on-the-colorectal-cancer-cells-via-downregulation-of-the-wnt-%C3%AE-catenin-signaling-pathway
#8
Shuang Wang, Huan Yang, Xin Chen, Zheng Jiang
AIM: To detect the function and mechanism of SOX15 in colorectal cancer. MATERIALS & METHODS: The expression of SOX15 in colorectal cancer (CRC) cells and tissues was detected by real-time PCR, quantitative real-time PCR and immunohistochemistry. The overexpression of SOX15 in cells was tested by western blot, CCK-8, FACS analysis, transwell and clone assay. Moreover, SOX15 regulated Wnt pathway investigated by western blot. RESULTS: We found that SOX15 has a low-expression in CRC cells and tissues...
July 18, 2018: Future Oncology
https://www.readbyqxmd.com/read/30004261/mismatch-repair-deficiency-assessment-by-immunohistochemistry-for-lynch-syndrome-screening-and-beyond
#9
Hui-Li Wong, Michael Christie, Lucy Gately, Jeanne Tie, Belinda Lee, Christine Semira, Sheau Wen Lok, Rachel Wong, Peter Gibbs
While mismatch repair (MMR) deficiency has been studied extensively, the assessment of MMR status in colorectal and other cancers remains highly relevant, particularly in light of recent data demonstrating that MMR deficiency is a strong predictor for treatment benefit with immune checkpoint inhibitors across multiple tumor types. In colorectal cancer, there is a growing consensus in support of routine MMR testing for Lynch syndrome screening, to inform prognosis and adjuvant chemotherapy use in early stage disease, and to predict response to immunotherapy in advanced disease...
July 13, 2018: Future Oncology
https://www.readbyqxmd.com/read/30001151/the-dignicap-scalp-cooling-system-and-its-use-in-the-treatment-of-chemotherapy-induced-alopecia
#10
Mollie M Mustoe, Carmen M Lee, Michelle E Melisko, Laura J Esserman, Hope S Rugo
Chemotherapy-induced alopecia remains an emotionally traumatic side effect for cancer patients that impacts the quality of life, may be protracted in duration and may influence treatment decisions. Scalp cooling has been shown to be effective in preventing chemotherapy-induced alopecia. The DigniCap Scalp Cooling System is designed to prevent hair loss by cooling the scalp to reduce the impact of chemotherapy on hair follicle cells. Recent studies have shown the safety, efficacy and low-grade toxicity of the DigniCap System with a 66...
July 12, 2018: Future Oncology
https://www.readbyqxmd.com/read/29992839/the-endoplasmic-reticulum-co-chaperone-erdj3-dnajb11-promotes-hepatocellular-carcinoma-progression-through-suppressing-aatz-degradation
#11
Junjiang Pan, Ding Cao, Jianping Gong
AIM: The co-chaperone ERdj3/DNAJB11 is involved in the endoplasmic reticulum stress response observed in cancer cells. We hypothesized that ERdj3 functions as a hepatocellular carcinoma (HCC) oncogene by inhibiting AATZ degradation. MATERIALS & METHODS: ERdj3 and AATZ expressions were analyzed in 84 HCC patients. Cell proliferation, epithelial-mesenchymal transition marker expression, migration and invasiveness were assessed in HepG2 and Huh-7 cells. A murine xenograft tumor model was constructed...
July 11, 2018: Future Oncology
https://www.readbyqxmd.com/read/29989443/tubular-carcinomas-of-the-breast-an-epidemiologic-study
#12
Jia-Yuan Sun, Juan Zhou, Wen-Wen Zhang, Feng-Yan Li, Zhen-Yu He, San-Gang Wu
AIM: We explored the clinicopathologic characteristics, prognostic factors and outcomes in tubular carcinoma (TC) of the breast. METHODS: We retrospectively assessed 8091 TC patients using the Surveillance, Epidemiology and End Results database from 2000 to 2013. RESULTS: Most patients were non-Hispanic white, well-differentiated disease, tumor size ≤2 cm, node-negative, nonmetastatic, hormone receptor-positive and HER2-negative status...
July 10, 2018: Future Oncology
https://www.readbyqxmd.com/read/29987957/deb-tace-a-standard-review
#13
Fabio Melchiorre, Francesca Patella, Lorenzo Pescatori, Filippo Pesapane, Enrico Fumarola, Pierpaolo Biondetti, Pietro Brambillasca, Cristian Monaco, Anna Maria Ierardi, Giuseppe Franceschelli, Gianpaolo Carrafiello
Drug-eluting bead transarterial chemoembolization (DEB-TACE) is a relative new endovascular treatment based on the use of microspheres to release chemotherapeutic agents within a target lesion with controlled pharmacokinetics. This aspect justifies the immediate success of DEB-TACE, that nowadays represents one of the most used treatments for unresectable hepatocellular carcinoma. However, there is no consensus about the choice of the best embolotherapy technique. In this review, we describe the available microspheres and report the results of the main comparative studies, to clarify the role of DEB-TACE in the hepatocellular carcinoma management...
July 10, 2018: Future Oncology
https://www.readbyqxmd.com/read/29987950/upregulation-of-long-noncoding-rna-malat1-in-papillary-thyroid-cancer-and-its-diagnostic-value
#14
Jia Liu, Hanhua Dong, Yingxu Yang, Yuejun Qian, Jianqiu Liu, Zhi Li, Hongya Guan, Zheng Chen, Cuilin Li, Ke Zhang, Qingsong Zhang, Wei Cao, Jing Lv
AIM: To investigate the expression level of lncRNA MALAT1 in papillary thyroid cancer (PTC) and evaluate its clinical diagnostic value as a biomarker in PTC. METHODS: MALAT1 lncRNA expression in tissues was detected by qRT-PCR. The diagnostic value of MALAT1 as a biomarker in PTC was evaluated with receiver operating characteristics. RESULTS: MALAT1 expression was upregulated in PTC tissues compared with paired corresponding noncancerous tissues...
July 10, 2018: Future Oncology
https://www.readbyqxmd.com/read/29978725/patient-selection-for-anti-pd-1-pd-l1-therapy-in-advanced-non-small-cell-lung-cancer-implications-for-clinical-practice
#15
Raffaele Califano, Rohit Lal, Conrad Lewanski, Marianne C Nicolson, Christian H Ottensmeier, Sanjay Popat, Matthew Hodgson, Pieter E Postmus
Immune checkpoint inhibitors (ICIs) targeting PD-1 or PD-L1 represent a standard treatment option for patients with advanced non-small-cell lung cancer. However, a substantial proportion of patients will not benefit from these treatments, and robust biomarkers are required to help clinicians select patients who are most likely to benefit. Here, we discuss the available evidence on the utility of clinical characteristics in the selection of patients with advanced non-small-cell lung cancer as potential candidates for single-agent anti-PD-1/PD-L1 therapy, and provide practical guidance to clinicians on identifying those patients who are most likely to benefit...
July 6, 2018: Future Oncology
https://www.readbyqxmd.com/read/29969917/smyd3-promoter-hypomethylation-is-associated-with-the-risk-of-colorectal-cancer
#16
Bin Li, Ranran Pan, Cong Zhou, Jie Dai, Yiyi Mao, Min Chen, Tianyi Huang, Xiuru Ying, Haochang Hu, Jun Zhao, Wei Zhang, Shiwei Duan
AIM: SMYD3 encodes histone lysine methyltransferase. The goal of our study was to investigate the association between SMYD3 methylation and colorectal cancer (CRC). MATERIALS & METHODS: SMYD3 methylation was measured by quantitative methylation-specific PCR method in 117 pairs of CRC tumor and para-tumor tissues. RESULTS: Significantly lower SMYD3 methylation was observed in CRC tumor tissues than para-tumor tissues (p = 0.002). Further subgroup analysis by clinical features showed that significantly lower SMYD3 methylation were only observed in the CRC patients with tumors of moderately and well differentiation, positive lymph node metastasis, and stage III + IV...
July 4, 2018: Future Oncology
https://www.readbyqxmd.com/read/29969285/systemic-inflammation-based-score-can-predict-prognosis-in-metastatic-gastric-cancer-patients-before-first-line-chemotherapy
#17
Angelica Petrillo, Maria Maddalena Laterza, Giuseppe Tirino, Luca Pompella, Jole Ventriglia, Annalisa Pappalardo, Vincenzo Famiglietti, Erika Martinelli, Fortunato Ciardiello, Michele Orditura, Gennaro Galizia, Ferdinando De Vita
AIM: Systemic inflammatory response affects survival of gastric cancer (GC) patients. This study was carried out to create a prognostic inflammatory-based score to predict survival in metastatic GC (mGC) before first-line chemotherapy. MATERIALS & METHODS: We studied the prognostic value of neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio in 151 patients with mGC at the diagnosis. RESULTS: Median overall survival (OS) was significantly lower in pts with high NLR...
July 3, 2018: Future Oncology
https://www.readbyqxmd.com/read/29957072/the-importance-of-science-communication-in-cancer-research-an-interview-with-martin-christlieb
#18
Martin Christlieb, Roshaine Wijayatunga
I trained as a chemist, studying for a PhD at the University of Cambridge. After I left Cambridge, I undertook postdoctoral appointments at Stanford and Oxford. These appointments led me into metal chemistry, initially using the metals as reagents, and finally using metal atoms as the key atom in a series of compounds designed to be radiolabeled markers of tumor hypoxia for positron emission tomography (PET) imaging. Finally I made the move to oncology to give my compounds a chance to be tested in a more biological setting...
June 29, 2018: Future Oncology
https://www.readbyqxmd.com/read/29956566/association-of-five-genetic-variations-in-dnmt1-and-dnmt3a-with-gastric-cancer-in-a-chinese-population
#19
Jin Zhou, Zhibing Wang, Lei Zhang, Yuanyuan Gu, Yong Ma, Xiangcheng Li
AIM: To determine whether genetic variations in DNMT1 and DNMT3A could be associated with gastric cancer risk. MATERIALS & METHODS: A total of 466 patients and 452 healthy controls were enrolled in this study. Genotypes were examined by using the Sequenom MassARRAY platform. RESULTS: No significant differences in the distribution frequencies were observed between the groups. However, subgroup analysis revealed that, in the group aged ≤60 years, DNMT3A rs13420827 was associated with reduced gastric cancer risk, and that carrier of GC/GG genotype was associated with reduced risk of gastric cancer with low differentiation or at the T3-T4 stage...
June 29, 2018: Future Oncology
https://www.readbyqxmd.com/read/29956562/neuro-oncology-perspective-of-treatment-options-in-metastatic-breast-cancer
#20
Riccardo Soffietti, Alessia Pellerino, Roberta Rudà
Breast cancer (BC) is a heterogeneous disease. Different subtypes of BC exhibit a peculiar natural history, metastatic potential and outcome. Stereotactic radiosurgery is the most used treatment for brain metastases (BM), while surgery is reserved for large and symptomatic lesions. Whole-brain radiotherapy is employed in multiple BM not amendable to radiosurgery or surgery, and it is not employed any more following local treatments of a limited number of BM. A critical issue is the distinction from pseudoprogression or radionecrosis, and tumor regrowth...
June 29, 2018: Future Oncology
journal
journal
41162
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"